Covifor, Cipremi and Fabiflu: COVID-19 Medicines approved by DCGI

Covifor, Cipremi and Fabiflu: Coronavirus Drugs approved by DCGI

COVID-19 cases in India have been rising for many days with total cases rising above 4 lakhs. The situation in the country is intense with the highest number of cases registered each day. Overall deaths of more than 13,000 have been recorded. With the ease in lockdown restrictions, many people are at the risk of getting contaminated. Also, there is no sign of a vaccine to be created anytime soon.

In such a crisis, pharmaceutical companies have brought a sigh of relief with medicines being produced for COVID-19 treatment. Three companies namely Cipla, Glenmark, and Hetero, have been given the permission to launch generic versions of Remdesivir and Favipiravir, anti-viral drugs useful for treating patients affected from Coronavirus. The three medicines are Covifor by Hetero, Cipremi by Cipla and Fabiflu by Glenmark. Let’s take a look at the three medicines that might have a chance to improve the condition of our country.

What is Plasma Therapy?

Prime Minister Narendra Modi Launches Garib Kalyan Rojgar Abhiyan Scheme

Fabiflu by Glenmark

Mumbai-based Glenmark Pharmaceuticals will manufacture Fabiflu, the generic version of Favipiravir, an anti-viral drug which has been approved in Japan for treating influenza. It has received approvals from DCGI. It is the first drug that can be taken orally. This is an oral medication that will treat mild to moderate COVID-19 cases. Every patient must have a signed prescription from a healthcare professional before having this medication. It is being tested in 18 clinical trials out of which results from 2 studies have shown positive outcomes. Officials have claimed that the drug shows clinical improvements of up to 88 percent. It will be available for Rs 103/tablet and is priced at Rs 3500 for 34 tablets. The drug price can be reduced further by 20-30 percent.

Indian China Trade At a Glance: Bilateral Trade and Investment

PM Narendra Modi Announces COVID Warriors Website

Covifor by Hetero

The new drug, termed as Covifor, is the second drug to enter the Indian market by Hetero for the treatment of coronavirus after Fabiflu by Glenmark, which came a day earlier. It had gotten the nod from Drug Controller General of India (DCGI) to launch antiviral Remdesivir as a treatment. The drug is injected intravenously and it would cost between 5,000 to 6,000 per dose. A five-day treatment course would not take more than Rs 30,000 per patient as confirmed by Hetero. The drug has to be given under the supervision of a healthcare professional and by prescription only. Hetero is one of India’s leading generic pharmaceutical firms and also the world’s largest producer of anti-retroviral drugs.

Click here to get the best study material for SSC CGL Tier 2 Exam 

Cipremi by Cipla 

Cipremi launched by Cipla is also a generic version of Remdesivir, an antiviral drug, first developed for the treatment of Ebola in 2014. This drug is also injected intravenously under the supervision of a doctor and a consent form must be signed by the patient before taking this drug. Cipla is yet to disclose the price but the drug can be effective in the treatment of COVID019 patients.

SSC Calendar 2020

UPSC Calendar 2020

The clinical trials of the mentioned drugs are still under process and the effectiveness of the drugs in COVID-19 treatment can be determined after the final results. Patients are advised to take the prescription of doctors before taking any of the drugs for the treatment.

May Current Affairs PDF

×

Download success!

Thanks for downloading the guide. For similar guides, free study material, quizzes, videos and job alerts you can download the Adda247 app from play store.

Thank You, Your details have been submitted we will get back to you.

Leave a comment

Your email address will not be published. Required fields are marked *

Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Login

OR

Forgot Password?

Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Sign Up

OR
Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Forgot Password

Enter the email address associated with your account, and we'll email you an OTP to verify it's you.


Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Enter OTP

Please enter the OTP sent to
/6


Did not recive OTP?

Resend in 60s

Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Change Password



Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Almost there

Please enter your phone no. to proceed
+91

Join India's largest learning destination

What You Will get ?

  • Job Alerts
  • Daily Quizes
  • Subject-Wise Quizes
  • Current Affairs
  • Previous year question papers
  • Doubt Solving session

Enter OTP

Please enter the OTP sent to Edit Number


Did not recive OTP?

Resend 60

By skipping this step you will not recieve any free content avalaible on adda247, also you will miss onto notification and job alerts

Are you sure you want to skip this step?

By skipping this step you will not recieve any free content avalaible on adda247, also you will miss onto notification and job alerts

Are you sure you want to skip this step?